Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764380 | 1.00 | CA1 (0.66) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL12222362 | 0.91 | CA1 (0.60) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL397022 | 0.90 | CA1 (0.78) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL28599438 | 0.89 | CA1 (0.62) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL28599440 | 0.89 | CA1 (0.62) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL24180413 | 0.87 | CA1 (0.64) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL21344946 | 0.87 | CA1 (0.64) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL19969955 | 0.86 | CA1 (0.53) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL9661261 | 0.85 | CA1 (0.66) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL3545404 | 0.85 | CA1 (0.65) | CA1CA2CA7CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100124-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115427109-A | Heterocyclic compounds as dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021156787-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156787-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
| US-8748660-B2 | Process for the synthesis of antiepileptic drug lacosamide | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-01-09 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20090216003-A1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | TINA HOLDING APS (DK) | 2009-08-27 | — | — | US | disclosed |
| WO-2007036494-A2 | AGROCHEMICAL FORMULATION COMPRISING POLYMER PARTICLES CONTAINING ACTIVE SUBSTANCES | BASF SE (DE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | GNE, GABRE, GALE | CA1 159/4885CA2 107/4885CA7 458/4885 |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | CA1 2021/4885CA2 883/4885CA7 3048/4885 |
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | CA1 4330/4885CA2 4374/4885CA7 3959/4885 |
| US-20090216003-A1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | PCNA, DNA2, NUDT1 | CA1 3431/4885CA2 2764/4885CA7 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.